



ONE STOP SOLUTION FOR ALL CRITICAL CARE MEDICINE LEARNING

"Master Classes in CRITICAL CARE MEDICINE"

(one and only successfully running digital learning platform in critical care medicine throughout the globe)

Dear all after the huge success of previous batches of "Master Classes in Critical Care Medicine", we are happy to announce the schedule of 11th batch from October 2024.



"FOR PREVIOUS BATCH DELEGATES- Registration amount - Rs 18,000 (220 USD) plus 18%GST"

**"FOR FIRST 100 REGISTRATIONS (for those who are not part of previous batches)
Registration amount - Rs 22,500 (275 USD) plus 18%GST"**

Now around
250 topics
included

(Above discount is valid till 15th September 2024)

{Regular price after the discounted period -Rs 30,000(365 USD) plus 18%GST}

Additional Features of Batch 11

- Recorded version of the classes will be available to watch as per your convenience for the entire tenure of the course (from the start date of the course to end of the course-total 6 months) on mobile/laptop/desktop with the individual login details
- To cover theory/practical points/MCQs of entire critical care medicine topics
- 10 Mock Tests with explanation of the answers included
- Case based approach to help CTCCM/IDCCM/IFCCM, EDIC/EDIAC II and DM/DrNB exit exams
- To discuss MCQs according to new pattern of NEET-SS and INI-CET critical care super speciality entrance exam
- Round the clock, one to one doubt clarification - to help practicing intensivists/ anaesthetists/ physicians/ pulmonologists / emergency physicians
- Continued academic support to registered delegates through "VOICE OF CRITICAL CARE MEDICINE" even after the batch is over
- With many more newer topics and MCQs included

Who should attend ?

- Those who are practicing Critical Care Medicine, Anaesthesia, Pulmonology, General Medicine and Emergency Medicine and interested to learn and upgrade the knowledge in critical care medicine.
- Those who are doing postgraduation in Anaesthesia, Pulmonology, General Medicine and Emergency Medicine and interested to choose Critical Care as career option.
- Those who are doing CTCCM, IDCCM, IFCCM, PDCC, FNB/DNB, DM in critical care.
- Those who are preparing for EDIC/EDIAC part I & II.
- Those who are preparing for NEET super speciality and INISS-CET entrance.



« SCAN HERE TO REGISTER

REGISTER NOW



**Classes will be starting
from October 2024**

COURSE FACULTY & DIRECTOR

Dr Harish Mallapura Maheshwarappa

MBBS, MD, DNB, IDCCM, DM (Critical Care Medicine TMH, Mumbai),
EDIC(Dublin), Fellowship in Infectious Diseases, FIARC, MBA

Intensive Care Physician and Infectious Disease Specialist

Mail : dr.harishmm@rocketmail.com

Call : +91-80952 18493

web : <https://harishcriticalcareclasses.com/>

For technical Queries call : +91 95381 15187



CURRICULUM

(now around 250 topics included)

INFECTIONS AND ANTI – INFECTIVES

1. SEPSIS – A CASE BASED APPROACH
2. SEPSIS GUIDELINES 2021- WHAT'S NEW?
3. EMPERIC ANTIBIOTIC APPROACH AND ANTIBIOTIC DEESCALATION IN ICU
4. COMMUNITY ACQUIRED PNEUMONIA
5. INVASIVE FUNGAL INFECTIONS – A CASE BASED APPROACH
6. NEWER ANTIBIOTICS IN THE PIPELINE
7. MDR GRAM NEGATIVES IN ICU: BASICS AND BEYOND
8. DIFFERENTIAL USAGE OF CARBAPENAMS: CURRENT EVIDENCE
9. APPROACH TO TROPICAL INFECTIONS IN ICU
10. PK – PD OF ANTIBIOTICS IN CRITICALLY ILL PATIENTS
- 11.
12. INTERPRETATION OF CULTURE SENSITIVITY REPORT: –MIC, BPC, MPC WHAT TO SEE AT THE BEDSIDE?
13. RAPID DIAGNOSTICS AND THERAPEUTIC DRUG MONITORING IN ICU : IS IT THE FUTURE?
14. TREATING HIV PATIENT : ICU PERSPECTIVE
15. INFECTION CONTROL POLICIES IN ICU:–CARING OF LINES, DRAINS AND PIPES, BIOMEDICAL WASTE MANAGEMENT, TRANSMISSION SPECIFIC ISOLATION PRECAUTIONS
16. IMMUNOMODULATION IN ICU WHAT IS THE EVIDENCE:–ULINASTATIN, METHYLENE BLUE , SEPSIVAC, THYMOCIN ALPHA, INTERFERON ALPHA MARIK'S PROTOCOL
17. MANAGING COMPLICATED UTI: AN OVERVIEW
18. OXA 48 AN EMERGING THREAT: WHAT WE SHOULD KNOW?
19. PULMONARY TB IN ICU: CHALLENGES IN DIAGNOSIS AND THERAPY
20. PYREXIA OF UNKNOWN ORIGIN: A PROTOCOLIZED APPROACH
21. MANAGEMENT OF COMPLICATED SKIN-SOFT TISSUE INFECTIONS IN ICU

HEAMODYNAMIC MONITORING

1. PRESSURE BASED INDECES / STATIC PARAMETERS–CVP, PAOP AND ARTERIAL LINE
2. CASE BASED DISCUSSION–VOLUME BASED INDECES / DYNAMIC PARAMETERS–PPV,SVV,SPV

3. CARDIAC OUTPUT MONITORING AN OVERVIEW
4. CARDIOGENIC SHOCK–CASE BASED APPROACH
5. OBSTRUCTIVE SHOCK–CASE BASED APPROACH
6. CASE BASED DISCUSSION– FLUID RESPONSIVENESS AND ADVANCED HEMODYNAMIC MONITORING:FLOW TRAC / VOLUME VIEW / PLR
7. FAST, eFAST, POCUS, BLUE PROTOCOL AND VEXUS SCORE: AN OVERVIEW

RESUSCITATION AND DERESUSCITATION

1. PCO2 GAP – PRACTICAL UTILITY AT THE BEDSIDE.
2. LACTATE IN NORMOTENSIVE PATIENTS : ITS CLINICAL RELEVANCE.
3. MICROCIRCULATORY ASSESSMENT IN ICU : WHERE WE ARE TODAY?
4. DE-RESUSCITATION IN ICU PATIENTS : WHEN AND WHICH PATIENTS TO BE INITIATED?

CARDIAC CRITICAL CARE

1. TREATING ATRIAL FIBRILLATION IN ICU
2. ACUTE CORONARY SYNDROME
3. ACUTE PULMONARY EMBOLISM
4. UNDERSTANDING DIASTOLIC DYSFUNCTION : CASE BASED APPROACH
5. NEWER DRUGS TO TREAT HEART FAILURE
6. MANAGEMENT OF SEPSIS INDUCED CARDIOMYOPATHY: CURRENT EVIDENCE
7. RIGHT HEART FAILURE IN ICU: A PROTOCOLIZED APPROACH
8. MECHANICAL CIRCULATORY SUPPORT DEVICES IN ICU (IABP, LVAD, IMPELLA): AN OVER VIEW
9. ECMO BASICS
10. ACLS/BLS
11. POST CARDIAC ARREST CARE
12. PACEMAKER IN ICU

ARDS

1. ARDS GENERAL AND VENTILATORY ASPECTS
2. LANDMARK TRAILS IN ARDS
3. UNDERSTANDING ARDS : CASE BASED APPROACH

CURRICULUM

(now around 250 topics included)

RESPIRATORY CRITICAL CARE

1. VENTILATOR ASSOCIATED PNEUMONIA
2. COPD – ICU MANAGEMENT
3. BRONCHIAL ASTHMA – ICU MANAGEMENT
4. AN EVIDENCE BASED MANAGEMENT OF COVID 19 IN ICU: AN OVERVIEW OF EVIDENCE TILL NOW
5. SYSTEMATIC APPROACH TO AIRWAY MANAGEMENT IN ICU: IS IT A DIFFERENT BALL GAME?
6. MASSIVE HEMOPTYSIS: A PROTOCOLIZED APPROACH
7. APPROACH TO PULMONARY ARTERY HYPERTENSION: AN OVERVIEW
8. TREATING PULMONARY FIBROSIS: AN EVIDENCE-BASED APPROACH
9. ACUTE EXACERBATION OF INTERSTITIAL LUNG DISEASE: AN EVIDENCE-BASED APPROACH

MECHANICAL VENTILATION

1. NON-INVASIVE VENTILATION:CURRENT EVIDENCE
2. HIGH FLOW NASAL CANULA: CURRENT EVIDENCE
3. BASICS OF VENTILATOR GRAPHICS
4. ADVANCED MODES OF MECHANICAL VENTILATION AN OVERVIEW
5. WEANING FAILURE AND DIFFICULTY IN WEANING
6. DIAPHRAGM PROTECTIVE VENTILATION : WHAT IT IS EXACTLY?
7. PATIENT SELF INFLICTED LUNG INJURY : UNDERSTANDING THE NEW CONCEPT.
8. LUNG STRESS AND STRAIN IN MECHANICAL VENTILATION.

FLUIDS, ELECTROLYTES & BLOOD

1. IV FLUID THERAPY IN ICU – CURRENT EVIDENCE
2. ALBUMIN IN ICU: WHEN, HOW MUCH AND WHICH PATIENTS?
3. APROACH TO HYPONATREMIA
4. APPROACH TO HYPERNATREMIA
5. MASSIVE TRANSFUSION PROTOCOL AND DAMAGE CONTROLLED RESUSCITATAION
6. AN APPROACH TO ARTERIAL BLOOD GAS ANALYSIS
7. ARTERIAL BLOOD GAS ANALYSIS PART II: STEWART'S APPROACH

8. TREATMENT OF HYPOKALEMIA IN ICU
9. TREATMENT OF HYPERKALEMIA IN ICU
10. TREATMENT OF HYPOMAGNESEMIA IN ICU
11. TREATMENT OF HYPERMAGNESEMIA IN ICU
12. TREATMENT OF HYPOPHOSPHATEMIA IN ICU
13. TREATMENT OF HYPERPHOSPHATEMIA IN ICU
14. TREATMENT OF HYPOCALCEMIA IN ICU
15. TREATMENT OF HYPERCALCEMIA IN ICU

ENDOCRINE AND NUTRITION

1. DIABETIC EMERGENCIES IN ICU: DKA, HHS & HYPOGLYCEAMIA
2. ACUTE ADRENAL INSUFFICIENCY: ICU MANAGEMENT
3. MANAGING HYPOTHYROIDISM AND MYXEDEMA COMA IN ICU: AN OVERVIEW
4. MANAGING HYPERTHYROIDISM AND THYROTOXICOSIS IN ICU: AN OVERVIEW
5. AN APPROACH TO ENTERAL NUTRITION IN ICU
6. DISEASE SPECIFIC NUTRITION
7. PHARMACO-NUTRITION
8. REFEEDING SYNDROME
9. TOTAL PARENTERAL NUTRITION: WHEN, HOW MUCH AND WHICH PATIENTS?

GUT, LIVER AND PANCREAS

1. CLOSTRIDIUM DIFFICILE DIARRHEA
2. SEVERE ACUTE PANCREATITIS
3. ACUTE FULMINANT LIVER FAILRE
4. ABDOMINAL COMPARTMENT SYNDROME
5. ICU MANAGEMENT OF UPPER GASTROINTESTINAL BLEED
6. ICU MANAGEMENT OF LOWER GASTROINTESTINAL BLEED

NEURO CRITICAL CARE

1. SUB ARACHNOID BLEED
2. MANAGING STROKE : ICU PERSPECTIVE
3. GB SYNDROME
4. MYASTHENIA GRAVIS
5. ICU ACQUIRED WEAKNESS

CURRICULUM

(now around 250 topics included)

6. TREATING MENINGITIS: ICU PERSPECTIVES
7. A STEPWISE APPROACH TO REFRACTORY STATUS EPILEPTICUS
8. AUTO IMMUNE ENCEPHALITIS: ICU PERSPECTIVE
9. ENCEPHALOPATHY IN ICU: METABOLIC
10. ENCEPHALOPATHY IN ICU: SEPTIC
11. TRANSCRANIAL DOPPLER AND ICP MONITORING: AN OVERVIEW
12. BRAIN DEATH DECLARATION AND ORGAN PRESERVATION

ONCO CRITICAL CARE AND HEAMATOLOGICAL ISSUES

1. TUMOUR LYSIS SYNDROME
2. HYPERLEUCOCYTOSIS SYNDROME
3. APPROACH TO FEBRILE NEUTROPENIA
4. OVERVIEW ON MANAGEMENT OF POST-TRANSPLANT PATIENT IN ICU
5. THROMBOTIC MICRO ANGIOPATHY IN ICU: - TTP
6. THROMBOTIC MICRO ANGIOPATHY IN ICU: - HUS
7. MACROPHAGE ACTIVATION SYNDROME/ HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH) SYNDROME IN ICU
8. ONCOLOGICAL EMERGENCIES PART II - SVC SYNDROME, SPINAL CORD COMPRESSION, PERICARDIAL EFFUSION AND CARCINOMATOSIS MENINGITIS
9. VISCOELASTIC TESTS OF HAEMOSTASIS (TEG AND ROTEM) : WORKING PRINCIPLES AND CLINICAL UTILITIES
10. BLEEDING AND COAGULOPATHY IN ICU: HOW TO APPROACH?
11. THROMBOCYTOPENIA / PLATELET DISORDERS IN ICU: DIFFERENTIAL DIAGNOSIS AND APPROACH
12. NEWER ANTI COAGULANTS AND DVT
13. STEROIDS IN ICU: WHEN, HOW MUCH AND WHICH PATIENTS?
14. IVIG IN ICU: WHEN, HOW MUCH AND WHICH PATIENTS?

TRAUMA/BURNS/SNAKE BITE/TOXICOLOGY/PREGNANCY

1. GENERAL VIEW ON ADVANCED TRAUMA LIFE SUPPORT (ATLS)
2. ABDOMINAL TRAUMA
3. TRAUMATIC BRAIN INJURY
4. AN EVIDENCE-BASED MANAGEMENT OF BURNS PATIENT IN ICU
5. ICU MANAGEMENT OF PATIENT WITH SNAKE BITE
6. TOXICOLOGY GENERAL APPROACH
7. MANAGEMENT OF CRITICALLY ILL PREGNANT PATIENT

PERI-OPERATIVE CRITICAL CARE

1. MANAGING CRITICALLY ILL POST SURGICAL PATIENT SEPSIS : A PRACTICAL CASE BASED APPROACH
2. MANAGING POST OPERATIVE MYOCARDIAL INFARCTION: PRACTICAL CONSIDERARTION
3. MANAGING POSTOPERATIVE PULMONARY EMBOLISM : PRACTICAL CONSIDERATIONS
4. PERI OPERATIVE ARRYTHMIA

NEPHRO CRITICAL CARE AND CONNECTIVE TISSUE DISORDERS

1. ACUTE KIDNEY INJURY
2. PRINCIPLES OF RENAL REPLACEMENT THERAPY
3. ROLE OF EXTRACORPOREAL FILTERS (CYTOSORB, OXARIS, TORAYMYXIN AND LPS ADSORBER) IN CRITICALLY ILL PATIENTS : WHERE WE ARE TODAY?
4. DIURETICS IN ICU: WHEN, HOW MUCH AND WHICH PATIENTS?
5. THERAPEUTIC PLASMA EXCHANGE IN ICU: WHAT IS THE EVIDENCE?
6. MANAGING CATASTROPHIC ANTI PHOSPHOLIPID ANTIBODY SYNDROME: ROLE OF INTENSIVIST
7. RHEUMATOLOGICAL EMERGENCIES IN ICU: AN OVERVIEW

CURRICULUM

(now around 250 topics included)

ORGAN CROSSTALKS IN ICU

1. Organ crosstalk in ICU patients: –Cardiorenal syndrome
2. Organ crosstalk in ICU patients: – Pulmonary renal syndrome
3. Organ crosstalk in ICU patients: – Hepatorenal syndrome

ICU ORGANISATION/ QUALITY ISSUES /END OF LIFE CARE

1. ICU ORGANISATION AND STRUCTURE : WHAT WE NEED TO UNDERSTAND ?
2. SCORING SYSTEM IN ICU
3. QUALITY INDICATORS IN ICU: AN OVERVIEW
4. HOW TO DO CLINICAL AUDIT IN ICU?
5. COMMUNICATION IN ICU: ITS SHORTFALLS AND HOW TO IMPROVE IT?
6. TRANSPORTING A CRITICALLY ILL PATIENT: PREPARATION AND TROUBLESHOOTING?
7. QUALITY INDICATORS IN ICU: AN OVERVIEW
8. BUNDLE CARE APPROACH IN ICU
9. END OF LIFE CARE PRINCIPLES
10. WHAT IS NEW IN END-OF-LIFE CARE POLICY – INDIAN SCENARIO?
11. HOW TO DO CRITICAL APPRAISAL OF PAPER?
12. IMAGING IN ICU
13. CRITICAL APPRAISAL OF LAND MARK TRAILS IN ICU

PRACTICAL POINTS TO REMEMBER ON ANTIBIOTICS, ANTIVIRALS AND ANTIFUNGALS: AN INTENSIVIST PERSPECTIVE

1. AN OVERVIEW ON DOXYCYCLINE, TIGECYCLINE AND MINOCYCLINE
2. AN OVERVIEW ON GLYCOPEPTIDES IN ICU: VANCOMYCIN AND TEICOPLANIN
3. AN OVERVIEW ON LINEZOLID
4. AN OVERVIEW ON CLINDAMYCIN
5. AN OVERVIEW ON DAPTOMYCIN
6. AN OVERVIEW ON FOSFOMYCIN USE IN ICU
7. AN OVERVIEW ON LEVONADIFLOXACIN: A NOVEL

8. AN OVERVIEW ON POLYMYXINS IN ICU
9. AN OVERVIEW ON ARBEKACIN
10. AN OVERVIEW ON ROLE OF CEFTRIAXONE SULBACTAM DISODIUM EDETATE IN THE ICU
11. AN OVERVIEW ON CEFTAROLINE
12. AN OVERVIEW ON CEFTAZIDIME AVIBACTAM AND AZTREONAM AVIBACTAM
13. AN OVERVIEW ON AZTREONAM AVIBACTAM
14. AN OVERVIEW ON HIGH DOSE SULBACTAM
15. AN OVERVIEW ON ECHINOCANDINS: ANIDULAFUNGIN, MICAUFUNGIN AND CASPOFUNGIN
16. AN OVERVIEW ON ERTAPENEM
17. AN OVERVIEW ON FAROPENEM
18. AN OVERVIEW ON VORICONAZOLE
19. AN OVERVIEW ON ISAVUCONAZOLE
20. AN OVERVIEW ON POSACONAZOLE
21. AN OVERVIEW ON AMPHOTERICIN –B
22. AN OVERVIEW ON ANTIVIRALS: – ACYCLOVIR
23. AN OVERVIEW ON ANTIVIRALS: – GANCICLOVIR
24. AN OVERVIEW ON ANTIVIRALS: – VALGANCYCLOVIR
25. AN OVERVIEW ON ANTIVIRALS: – FOSCARNET
26. VABORBACTUM AND ITS COMBINATIONS (MEROPENEM-VABORBACTUM): AN OVERVIEW?
27. RELEBACTAM AND ITS COMBINATIONS (IMIPENEM-RELEBACTAM): CURRENT EVIDENCE
28. CLINICAL EVIDENCE ON TANIBORBACTAM COMBINATIONS (CEFEPIME-TANIBORBACTAM)
29. CLINICAL UTILITY AND EVIDENCE ON CEFIDEROCOL

PRACTICAL POINTS TO REMEMBER ON VASOACTIVE AGENTS: AN INTENSIVIST PERSPECTIVE

1. AN OVERVIEW ON ADRENALINE: CURRENT EVIDENCE IN ICU
2. NORADRENALINE: CLINICAL UTILITY AND EVIDENCE
3. DOPAMINE IN ICU: WHEN, WHICH PATIENTS AND HOW MUCH?
4. DOBUTAMINE: IS IT A WONDER IONODILATOR?
5. LEVOSIMENDAN: WHERE IS THE PLACE AMONG CRITICALLY ILL PATIENTS?
6. CLINICAL UTILITY AND CURRENT EVIDENCE ON VASOPRESSIN

CURRICULUM

(now around 250 topics included)

6. CLINICAL UTILITY AND CURRENT EVIDENCE ON VASOPRESSIN
7. TERLIPRESSIN IN CRITICAL CARE UNIT: BEYOND ITS ROUTINE USE
8. ANGIOTENSIN II IN VASODILATORY SHOCK: CURRENT EVIDENCE
9. PHENYLEPHRINE: WHEN AND WHICH PATIENTS TO USE?
10. MILRINONE IN MEDICAL ICU: CURRENT EVIDENCE
11. CENTHAQUINE- A NEW MEDICATION FOR HYPOVOLEMIC SHOCK: CURRENT EVIDENCE

“ADDITIONAL TOPICS INCLUDED IN BATCH II”

1. CITRATE ANTICOAGULATION DURING CRRT: CURRENT EVIDENCE
2. HYPOTENSION PREDICTION INDEX (HPI): NEW CONCEPT IN HEMODYNAMIC MONITORING
3. NEW CONCEPT IN HEMODYNAMIC MONITORING: PULSE WAVE TRANSIT TIME
4. RENAL RESISTIVE INDEX TO PREDICT AKI: METHODOLOGY AND EVIDENCE
5. CARBAPENEM RESISTANT ENTEROBACTERIACEAE AND THE OPTIONS AVAILABLE : AN OVERVIEW
6. DALBAVANCIN: AN OVERVIEW
7. PLAZOMYCIN : AN OVERVIEW
8. AVIPTADIL -A SYNTHETIC FORM OF VASOACTIVE INTESTINAL PEPTIDE IN ARDS: CURRENT EVIDENCE
9. CATHETER-RELATED BLOODSTREAM INFECTION (CRBSI) AND CENTRAL LINE-ASSOCIATED BLOODSTREAM INFECTION (CLABSI) : AN OVERVIEW
10. INHALED ANTI-INFECTIVES (ANTIBIOTICS AND ANTIFUNGALS) IN ICU : CURRENT EVIDENCE

11. WHAT'S NEW IN THE MANAGEMENT OF ACUTE SEVERE PANCREATITIS IN THE ICU
12. TRALI AND TACO : AN OVERVIEW
13. LIVER DISEASES DURING PREGNANCY: ACUTE FATTY LIVER OF PREGNANCY
14. LIVER DISEASES DURING PREGNANCY: HELLP
15. LIVER DISEASES DURING PREGNANCY: INTRA HEPATIC CHOLESTASIS
16. APPROACH TO METHEMOGLOBINEMIA IN ICU
17. APPROACH TO CORBON MONOXIDE POISONING IN ICU
18. APPROACH TO PARAQUAT POISONING : AN OVERVIEW
19. APPROACH TO RODENTICIDE OR RATOL POISONING : AN OVERVIEW
20. RIGHT VENTRICLE-PROTECTIVE VENTILATION : HOW TO APPROACH
21. WHAT IS NEW IN ARDS : UNDERSTANDING DIFFERENT PHENOTYPES
22. WHAT IS NEW IN ARDS : ADJUVANT THERAPIES
23. EXTRACORPOREAL CO2 REMOVAL: WHEN AND WHICH PATIENTS?
24. MANAGING HEATSTROKE IN ICU : AN OVERVIEW
25. APPROACH TO AN UNCONSCIOUS PATIENT : AN OVERVIEW
26. APPROACH TO HYPOGLYCEMIA IN ICU : AN OVERVIEW
27. APPROACH TO NEW ONSET OF FEVER IN ICU
28. STEPWISE APPROACH TO HYPOXIC RESPIRATORY FAILURE
29. STEPWISE APPROACH TO HYPERCAPNIC RESPIRATORY FAILURE
30. MANAGING SICKLE CELL CRISIS IN ICU

COURSE FACULTY & DIRECTOR

Dr Harish Mallapura Maheshwarappa

MBBS, MD, DNB, IDCCM, DM (Critical Care Medicine TMH, Mumbai),
EDIC(Dublin), Fellowship in Infectious Diseases, FIARC, MBA

Intensive Care Physician and Infectious Disease Specialist

Mail : dr.harishmm@rocketmail.com

Call : +91-80952 18493

For technical assistance: Mr Anil - +91-95381 15187



FEES STRUCTURE

CATEGORY		FOR FIRST 100 REGISTRATIONS - 25% DISCOUNT TILL 15TH SEPTEMBER 2024	15% EXTENDED DISCOUNT- 16TH SEPTEMBER TO 15TH OCTOBER 2024	REGULAR - WITHOUT DISCOUNT-15TH OCTOBER 2024 ONWARDS
INDIAN DELEGATES (INR)	Registration fee	30000	30000	30000
	Discount	7500	4500	0
	Amount after discount	22500	25500	30000
	GST 18%	4050	4590	5400
	Total amount payable	26550	30090	35400
FOREIGN DELEGATES (USD)	Registration fee	365	365	365
	Discount	90	55	0
	Amount after discount	275	310	365
	GST 18%	50	55	65
	Total amount payable	325	365	430

**CLASSES WILL BE STARTING FROM
OCTOBER 2024**



SCAN HERE TO REGISTER

CLICK HERE TO REGISTER

